Article

Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai.

Department of Infectious Diseases, Children's Hospital of Fudan University, Shanghai 201102, China.
Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology (impact factor: 3.12). 01/2012; 53(4):285-9. DOI:10.1016/j.jcv.2011.12.025 pp.285-9
Source: PubMed

ABSTRACT In 2010, China experienced the largest outbreak on record of Enterovirus 71 (EV71)-associated Hand Foot and Mouth Disease (HFMD) with more than 1.7 million cases, 27,000 patients with severe neurological complications and 905 deaths. Understanding of the seroprevalence of neutralizing antibodies (NAb) against EV71 and their protective role against HFMD in children is crucial for the implementation of future therapeutic and prophylactic intervention.
To correlate the prevalence of NAb against EV71 genotype C4a in children prior to the 2011 epidemic season with severe EV71-associated HFMD disease during the subsequent 2011 epidemic season.
614 sera samples were collected from children without HFMD. EV71 NAb were tested by a quantitative PCR assay. Samples with NAb ≥1:8 were scored as positive.
122 (19.9%) of 614 sera were EV71-seropositive. The NAb seroprevalence was highest in infants 0-5 months of age (28.6%) and lowest in children 1-1.9 years of age (13.4%). 64.1% of severe EV71-associated HFMD occurred in children 1-2.9 years.
Despite the large 2010 outbreak, the overall seroprevalence of EV71 in children is relatively low. The seropositive rate of EV71 NAb prior to the 2011 season was inversely correlated with the number of EV71-infected severe cases in 2011. Loss of maternal antibodies in infants and lack of acquired anti-EV71 immunity are responsible for increased proportion of severe HFMD in the 1-2 years age group. Our data suggest that future vaccination campaigns should be initiated as early as 6 months.

0 0
 · 
0 Bookmarks
 · 
29 Views

Keywords

1.7 million cases
 
2011 epidemic season
 
6 months
 
children 1-1.9 years
 
children 1-2.9 years
 
EV71 genotype C4a
 
EV71)-associated Hand Foot
 
EV71-infected severe cases
 
future vaccination campaigns
 
infants 0-5 months
 
large 2010 outbreak
 
Mouth Disease
 
NAb seroprevalence
 
protective role
 
quantitative PCR assay
 
seropositive rate
 
severe EV71-associated HFMD
 
severe EV71-associated HFMD disease
 
severe neurological complications
 
subsequent 2011 epidemic season
 

Mei Zeng